Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424356 | 1.00 | TRPA1 (0.42) | TRPA1POLBCNR1CNR2CYP2D6 | |
| SCHEMBL24267448 | 1.00 | TRPA1 (0.42) | TRPA1POLBCNR1CNR2CYP2D6 | |
| SCHEMBL21947333 | 1.00 | TRPA1 (0.42) | TRPA1POLBCNR1CNR2CYP2D6 | |
| SCHEMBL21961818 | 0.86 | — | — | |
| SCHEMBL25090773 | 0.86 | — | — | |
| SCHEMBL24618891 | 0.86 | — | — | |
| SCHEMBL28566656 | 0.80 | POLB (0.33) | POLB | |
| SCHEMBL1153330 | 0.78 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL1153334 | 0.78 | TRPA1 (0.39) | TRPA1 | |
| SCHEMBL1153332 | 0.78 | TRPA1 (0.39) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131201-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TRPA1 4793/4885POLB 1657/4885CNR1 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.